CD8 + T cell infiltration is associated with improved survival and negatively correlates with hypoxia in clear cell ovarian cancer.
Female
Humans
Antigens, Neoplasm
/ metabolism
Biomarkers, Tumor
/ metabolism
Canada
Carbonic Anhydrase IX
Carbonic Anhydrases
/ metabolism
Hypoxia
/ pathology
Ovarian Neoplasms
/ metabolism
Positron Emission Tomography Computed Tomography
Prognosis
Lymphocytes, Tumor-Infiltrating
CD8-Positive T-Lymphocytes
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 04 2023
21 04 2023
Historique:
received:
30
10
2022
accepted:
27
02
2023
medline:
25
4
2023
pubmed:
22
4
2023
entrez:
21
04
2023
Statut:
epublish
Résumé
Unlike other histological types of epithelial ovarian carcinoma, clear cell ovarian carcinoma (CCOC) has poor response to therapy. In many other carcinomas, expression of the hypoxia-related enzyme Carbonic anhydrase IX (CAIX) by cancer cells is associated with poor prognosis, while the presence of CD8 + tumor-infiltrating lymphocytes (TIL) is positively prognostic. We employed [
Identifiants
pubmed: 37085560
doi: 10.1038/s41598-023-30655-3
pii: 10.1038/s41598-023-30655-3
pmc: PMC10121667
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Carbonic Anhydrase IX
EC 4.2.1.1
Carbonic Anhydrases
EC 4.2.1.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6530Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2023. The Author(s).
Références
Front Immunol. 2021 May 20;12:680435
pubmed: 34093582
EBioMedicine. 2019 Dec;50:203-210
pubmed: 31761620
Breast Cancer Res Treat. 2022 Jul;194(1):13-23
pubmed: 35482128
BMC Cancer. 2018 Mar 27;18(1):347
pubmed: 29587661
Gynecol Oncol. 2011 Jul;122(1):107-10
pubmed: 21463887
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Cancer Discov. 2012 Jul;2(7):608-23
pubmed: 22719018
Gynecol Oncol. 2008 Jun;109(3):370-6
pubmed: 18395777
PLoS One. 2013 Dec 23;8(12):e82406
pubmed: 24376535
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Mol Omics. 2021 Apr 1;17(2):307-316
pubmed: 33624645
Gynecol Oncol. 2007 Aug;106(2):311-7
pubmed: 17532031
Nat Rev Cancer. 2008 Sep;8(9):705-13
pubmed: 19143055
J Clin Invest. 2021 Apr 1;131(7):
pubmed: 33792560
Radiother Oncol. 2021 Jun;159:75-81
pubmed: 33753155
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
J Immunol. 2009 Mar 15;182(6):3510-21
pubmed: 19265129
Elife. 2020 Nov 23;9:
pubmed: 33226340
Annu Rev Med. 2022 Jan 27;73:251-265
pubmed: 34699264
Front Immunol. 2021 May 07;12:660944
pubmed: 34025660
Front Immunol. 2020 Aug 21;11:1906
pubmed: 32973789
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Gynecol Oncol. 2016 Apr;141(1):95-100
pubmed: 27016234
Cell Physiol Biochem. 2017;41(4):1271-1284
pubmed: 28278498
Nat Immunol. 2021 Feb;22(2):205-215
pubmed: 33398183
Nature. 2017 Oct 11;550(7675):204-213
pubmed: 29022597
Oncogene. 2010 Mar 25;29(12):1741-52
pubmed: 20062075
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
Front Oncol. 2020 May 15;10:796
pubmed: 32500034
J Transl Med. 2021 Jan 6;19(1):9
pubmed: 33407613
PLoS One. 2011;6(7):e21121
pubmed: 21754983
Cancers (Basel). 2020 Dec 17;12(12):
pubmed: 33348579
In Vivo. 2022 Jan-Feb;36(1):212-220
pubmed: 34972717
J Ovarian Res. 2019 Jan 24;12(1):7
pubmed: 30678691
Nat Rev Cancer. 2014 Jun;14(6):430-9
pubmed: 24827502
Cancer Res. 2006 Feb 1;66(3):1354-62
pubmed: 16452189
J Pathol. 2012 Dec;228(4):437-47
pubmed: 22926683